Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Wheeler

Showing results (391-400 of 455) with videos related to

Pageof 46
Sort By:
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 8, 2023
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical TrialTae Won Yi, Brendan Smyth, Gian Luca Di Tanna, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 25, 2018
Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic ReviewBénédicte Sautenet, Allison Tong, Gabrielle Williams, et al.
Kidney International Reports|August 13, 2021
Randomized Trial-PrEscription of intraDialytic exercise to improve quAlity of Life in Patients Receiving HemodialysisSharlene A Greenwood, Pelagia Koufaki, Jamie H Macdonald, et al.
Diabetes & Metabolism|February 16, 2022
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trialJinlan Liao, Amy Kang, Chao Xia, et al.
Journal of the American College of Cardiology|June 16, 2018
Cardiovascular Outcomes Reported in Hemodialysis TrialsEmma O'Lone, Andrea K Viecelli, Jonathan C Craig, et al.
Journal of the American Heart Association|March 9, 2022
Dialysis Initiation in Patients With Chronic Coronary Disease and Advanced Chronic Kidney Disease in ISCHEMIA-CKDCarlo Briguori, Roy O Mathew, Zhen Huang, et al.
American Heart Journal|September 11, 2017
A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trialManvir K Hayer, Nicola C Edwards, Gemma Slinn, et al.
Clinical Kidney Journal|July 12, 2021
Methods and rationale of the DISCOVER CKD global observational studyRoberto Pecoits-Filho, Glen James, Juan Jesus Carrero, et al.
Health Technology Assessment (Winchester, England)|June 22, 2021
Exercise programme to improve quality of life for patients with end-stage kidney disease receiving haemodialysis: the PEDAL RCTSharlene A Greenwood, Pelagia Koufaki, Jamie H Macdonald, et al.
Kidney International|April 6, 2023
Defining myocardial infarction in trials of people receiving hemodialysis: consensus report from the SONG-HD MI Expert Working groupEmma O'Lone, Fred S Apple, James O Burton, et al.
Pageof 46

Showing results (391-400 of 455) with videos related to

Sort By:
Pageof 46
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 8, 2023
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical TrialTae Won Yi, Brendan Smyth, Gian Luca Di Tanna, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 25, 2018
Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic ReviewBénédicte Sautenet, Allison Tong, Gabrielle Williams, et al.
Kidney International Reports|August 13, 2021
Randomized Trial-PrEscription of intraDialytic exercise to improve quAlity of Life in Patients Receiving HemodialysisSharlene A Greenwood, Pelagia Koufaki, Jamie H Macdonald, et al.
Diabetes & Metabolism|February 16, 2022
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trialJinlan Liao, Amy Kang, Chao Xia, et al.
Journal of the American College of Cardiology|June 16, 2018
Cardiovascular Outcomes Reported in Hemodialysis TrialsEmma O'Lone, Andrea K Viecelli, Jonathan C Craig, et al.
Journal of the American Heart Association|March 9, 2022
Dialysis Initiation in Patients With Chronic Coronary Disease and Advanced Chronic Kidney Disease in ISCHEMIA-CKDCarlo Briguori, Roy O Mathew, Zhen Huang, et al.
American Heart Journal|September 11, 2017
A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trialManvir K Hayer, Nicola C Edwards, Gemma Slinn, et al.
Clinical Kidney Journal|July 12, 2021
Methods and rationale of the DISCOVER CKD global observational studyRoberto Pecoits-Filho, Glen James, Juan Jesus Carrero, et al.
Health Technology Assessment (Winchester, England)|June 22, 2021
Exercise programme to improve quality of life for patients with end-stage kidney disease receiving haemodialysis: the PEDAL RCTSharlene A Greenwood, Pelagia Koufaki, Jamie H Macdonald, et al.
Kidney International|April 6, 2023
Defining myocardial infarction in trials of people receiving hemodialysis: consensus report from the SONG-HD MI Expert Working groupEmma O'Lone, Fred S Apple, James O Burton, et al.
Pageof 46